Mark Cuban is attempting to improve the U.S. healthcare system through his company, Cost Plus Drugs, which seeks to challenge pharmacy benefit managers. He has been known for his significant investments in publicly-traded companies, including Amazon, Meta, and Google. These companies are positioned to benefit from the AI revolution. Investors are encouraged to consider Cuban's stock selections for long-term growth opportunities. Additionally, a report titled "The Next NVIDIA" offers insights into AI stocks with substantial profit potential.
Mark Cuban has discussed at length his plans for Cost Plus Drugs, a rather remarkable business he launched to try to take market share from pharmacy benefit managers (PBMs), which dominate a good chunk of the U.S. healthcare system.
AMZN, META and GOOG are all highly leveraged to the emerging AI revolution.
Cuban has been critical of Amazon (NASDAQ:AMZN) in the past, noting the e-commerce giant remains the billionaire investor's largest publicly-traded holding in his portfolio.
If you're looking for a megatrend with massive potential, make sure to grab a complimentary copy of our "The Next NVIDIA" report.
Collection
[
|
...
]